ArticleMolecular imaging and radionuclide therapy2026
Papillary Thyroid Microcarcinomas Detected by Nuclear Medicine Imaging: Distinct Clinicopathological Features Compared with Conventional Modalities.
Article in Molecular imaging and radionuclide therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Papillary thyroid carcinomas detected by nuclear medicine imaging techniques may have a worse prognosis than those identified by conventional methods. However, it remains unclear whether this applies to papillary thyroid microcarcinomas (PTMCs). Methods: Patients diagnosed with PTMC at Hacettepe University Faculty of Medicine between 2008 and 2020 were categorized into three groups: (1) incidental PTMCs (Inc-PTMC; n=249), (2) non-incidental PTMCs (NonInc-PTMC; n=134), and (3) PTMCs detected by nuclear medicine imaging methods (NM-PTMC; n=24). Tumor pathological characteristics, including multifocality, extrathyroidal extension, vascular invasion, and lymph node involvement, were analyzed. Logistic regression analysis was performed to assess the association between detection method and tumor aggressiveness while adjusting for potential confounders. Results: Patients in NM-PTMC group were significantly older at diagnosis (54.7±11.2 years) than those in Inc-PTMC (51.1±11.3 years) and NonInc-PTMC (46.9±11.7 years, p=0.001) groups. Tumor size was larger in NM-PTMCs (4.8±2.5 mm) and NonInc-PTMCs (5.3±2.2 mm) compared to Inc-PTMCs (3.4±2.4 mm, p<0.0001). Multiple logistic regression analysis revealed that NM-PTMCs had a markedly higher risk of cervical lymph node metastasis compared with both Inc-PTMCs [odds ratio (OR): 36.04; 95% confidence interval (CI): 6.02-215.59, p=0.001) and NonInc-PTMCs (OR: 8.68; 95% CI: 1.15-65.22, p=0.036). NM-PTMC also had an increased risk of positive surgical margins compared with Inc-PTMC (OR: 5.08; 95% CI: 1.57-16.39, p=0.006), whereas only NonInc-PTMC had a higher risk of extrathyroidal extension (OR: 3.19; 95% CI: 1.48-8.84, p=0.003). The detection method was not associated with multifocality. Conclusion: Nuclear medicine-detected PTMCs may differ in their clinicopathological profile from other PTMC subgroups and may represent an intermediate phenotype between Inc-PTMC and NonInc-PTMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.